Preview

Современная ревматология

Расширенный поиск

Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report

https://doi.org/10.14412/1996-7012-2021-4-68-71

Полный текст:

Об авторах

O. Psenak
Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Centre; Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University; Cancer Cluster Salzburg
Австрия


R. Greil
Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Centre; Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University; Cancer Cluster Salzburg
Австрия


Литература

1. Greco A, Marinelli C, Fusconi M, et al. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol. 2016 Jun;29(2):151-59. doi:10.1177/0394632015617063.

2. Tervaert JWC. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis. Curr Opin Rheumatol. 2018 Jul;30(4):388-94. doi:10.1097/BOR.0000000000000508.

3. Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore). 2007 Sep;86(5):269-77. doi:10.1097/MD.0b013e3181568ec0.

4. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012 Jun;71(6):955-60. doi:10.1136/annrheumdis-2011-200477.

5. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi:10.1056/NEJMoa0909905.

6. Aydin Z, Gursu M, Karadag S, et al. Role of plasmapheresis performed in hemodialysis units for the treatment of anti-neutrophilic cytoplasmic antibody-associated systemic vasculitides. Ther Apher Dial. 2011 Oct; 15(5):493-98. doi:10.1111/j.1744-9987.2011.00960.x.

7. Oiwa H, Yamasaki S, Endo K, et al. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remissioninduction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol. Intern Med. 2014; 53(20):2291-96. doi:10.2169/internalmedicine.53.2553.

8. Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi:10.1111/eci.12410.

9. Just SA, Knudsen JB, Nielsen MK, Junker P. Wegener's granulomatosis presenting with pachymeningitis: clinical and imaging remission by rituximab. ISRN Rheumatol. 2011;2011: 608942. doi:10.5402/2011/608942.

10. Puechal X, Pagnoux C, Perrodeau E, et al. Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. Arthritis Rheumatol. 2016 Mar; 68(3):690-701. doi:10.1002/art.39450.

11. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. doi:10.1056/NEJMoa1404231.

12. de Joode AAE, Sanders JSF, Puechal X, et al. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology (Oxford). 2017 Nov 1;56(11): 1894-1901. doi:10.1093/rheumatology/kex281.

13. Qaisar H, Shenouda M, Shariff M, et al. Granulomatosis with Polyangiitis Manifesting as Refractory Otitis Media and Mastoiditis. Arch Iran Med. 2019 Jul 1;22(7):410-13.

14. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol. 2003 Jan;30(1):80-8.

15. de Groot K, Adu D, Savage CO; EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001 Oct; 16(10):2018-27. doi:10.1093/ndt/16.10.2018.

16. Partsch H. Supplementary instrumental examinations in the most frequently occurring peripheral vascular diseases in general practice. Hautarzt. 1985 Apr;36(4):203-11.

17. Foti R, Visalli E, Amato G, et al. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. Rheumatol Int. 2017 Feb; 37(2):245-49. doi:10.1007/s00296016-3582-4.

18. Yusof MY, Vital EM, Das S, et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Ann Rheum Dis. 2015 Sep; 74(9):1734-38. doi:10.1136/annrheumdis-2014-206496.

19. Bramsiepe I, Danz B, Heine R, et al. Primary cutaneous manifestation of Wegener's granulomatosis. Dtsch Med Wochenschr. 2008 Jul;133(27):1429-32. doi:10.1055/s-2008-1081089.

20. Schmidt WA, Both M, Reinhold-Keller E. Imaging procedures in rheumatology: imaging in vasculitis. Z Rheumatol. 2006 Nov;65(7):652-56, 658-61. doi:10.1007/s00393-006-0107-7.


Для цитирования:


Psenak O., Greil R. Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report. Современная ревматология. 2021;15(4):68-71. https://doi.org/10.14412/1996-7012-2021-4-68-71

For citation:


Psenak O., Greil R. Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report. Modern Rheumatology Journal. 2021;15(4):68-71. https://doi.org/10.14412/1996-7012-2021-4-68-71

Просмотров: 84


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)